As New CEO of Cerevel, Coles Moves From One Neuro Startup to Another
Summary
Coles on Monday was named the CEO of Cerevel Therapeutics, a Boston company that Pfizer (NYSE: PFE) and Bain Capital launched in October 2018 with $350 million in funding. The appointment marks the latest chief executive gig at a biotech startup for Coles, a longtime life sciences executive who helped restructure NPS Pharmaceuticals—which was eventually acquired by Shire—and led Onyx Pharmaceuticals to a sale to Amgen (NASDAQ: AMGN) in 2013. In December 2014, Coles emerged as the CEO (and a founding investor) of Yumanity Therapeutics, a startup developing drugs for neurodegenerative diseases like Parkinson’s and Alzheimer’s. The startup was based on the work of Susan Lindquist, a highly decorated researcher and National Medal of Science winner who founded FoldRx (which was acquired by Pfizer in 2010). Lindquist passed away in 2016, and Coles moved from CEO to executive chairman in July of this year.
Classifications
AskAI Classifications
LabelsLinked Companies
